Overcoming therapeutic resistance in driver-negative NSCLC: Immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort
Abstract Background Driver gene-negative advanced non-squamous non-small cell lung cancer (NSCLC) exhibits inherent resistance to conventional therapies, representing a significant treatment challenge. The limited efficacy of platinum-based chemotherapy alone underscores the need for resistance-miti...
Saved in:
| Main Authors: | Yan Ge, Yang Zhao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02926-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial
by: Shuyu Ji, et al.
Published: (2025-07-01) -
Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
by: Qi Zhao, et al.
Published: (2025-08-01) -
Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy
by: Zheng X, et al.
Published: (2025-06-01) -
Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report
by: Xuhua Huang, et al.
Published: (2024-12-01) -
Use of camrelizumab in treatment of nasopharyngeal carcinoma
by: Yu. V. Alymov, et al.
Published: (2024-12-01)